趋化因子受体2是腹主动脉瘤的一种诊疗生物标志物。

Chemokine Receptor 2 Is a Theranostic Biomarker for Abdominal Aortic Aneurysms.

作者信息

Elizondo-Benedetto Santiago, Sastriques-Dunlop Sergio, Detering Lisa, Arif Batool, Heo Gyu Seong, Sultan Deborah, Luehmann Hannah, Zhang Xiaohui, Gao Xuefeng, Bredemeyer Andrea, Zaghloul Mohamed S, Harrison Kitty, Thies Dakkota, McDonald Laura, Combadière Christophe, Lin Chieh-Yu, Kang Yeona, Zheng Jie, Ippolito Joseph, Laforest Richard, Lavine Kory, Gropler Robert J, English Sean J, Zayed Mohamed A, Liu Yongjian

机构信息

Section of Vascular Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.

Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, USA.

出版信息

JACC Basic Transl Sci. 2025 Apr 23:101250. doi: 10.1016/j.jacbts.2025.02.010.

DOI:10.1016/j.jacbts.2025.02.010

PMID:40272356

Abstract

Abdominal aortic aneurysm (AAA) is a degenerative vascular disease with a high mortality upon rupture. There is no diagnosis to predict the rupture nor effective medical therapies to prevent rupture. Here we demonstrate that the C-C chemokine receptor type 2 (CCR2) is a theranostic biomarker for AAA. In rat AAA models, we determined the potential of a CCR2-targeted positron emission tomography radiotracer [Cu]Cu-DOTA-ECL1i predicting AAA rupture. Using a CCR2 inhibitor, we observed the effective prevention of rupture in AAA rat models. In humans, CCR2 positron emission tomography showed intense radiotracer uptake along the AAA wall in patients while little signal was observed in healthy volunteers.

摘要

腹主动脉瘤（AAA）是一种退行性血管疾病，破裂时死亡率很高。目前尚无诊断方法可预测其破裂，也没有有效的药物治疗来预防破裂。在此，我们证明C-C趋化因子受体2型（CCR2）是腹主动脉瘤的一种诊疗生物标志物。在大鼠腹主动脉瘤模型中，我们确定了一种靶向CCR2的正电子发射断层显像放射性示踪剂[Cu]Cu-DOTA-ECL1i预测腹主动脉瘤破裂的潜力。使用CCR2抑制剂，我们观察到在腹主动脉瘤大鼠模型中可有效预防破裂。在人类患者中，CCR2正电子发射断层显像显示，患者腹主动脉瘤壁有强烈的放射性示踪剂摄取，而在健康志愿者中几乎未观察到信号。